Young David 4
4 · Processa Pharmaceuticals, Inc. · Filed Aug 2, 2024
Insider Transaction Report
Form 4
Young David
DirectorPres. Research & Development
Transactions
- Exercise/Conversion
Common Stock
2024-07-10+644→ 81,187 total - Tax Payment
Common Stock
2024-04-05$2.79/sh−518$1,445→ 80,543 total - Tax Payment
Common Stock
2024-07-10$1.71/sh−282$482→ 80,905 total - Award
Restricted Stock Units
2024-06-28+3,233→ 21,922 totalExercise: $0.00→ Common Stock (3,233 underlying) - Award
Restricted Stock Units
2024-06-28+2,425→ 24,347 totalExercise: $0.00→ Common Stock (2,425 underlying) - Exercise/Conversion
Common Stock
2024-04-05+1,675→ 81,061 total - Award
Restricted Stock Units
2024-06-28+404→ 25,155 totalExercise: $0.00→ Common Stock (404 underlying) - Award
Restricted Stock Units
2024-06-28+404→ 24,751 totalExercise: $0.00→ Common Stock (404 underlying)
Holdings
- 10,786(indirect: By Family Entities)
Common Stock
- 30,985(indirect: By Trust)
Common Stock
- 18,544(indirect: By LLC)
Common Stock
Footnotes (4)
- [F1]Distribution of vested restricted shares.
- [F2]Each Restricted Stock Unit represents a contingent right receive one share of the Issuer's common stock, following its vesting on January 1, 2025.
- [F3]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.
- [F4]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.